Novartis Ag · SIX:NOVN
Novartis — Q1 2026 Earnings Presentation
85 slides from Novartis's earnings presentation, Apr 28, 2026
Slide 1: Q1 2026 Investor Presentation Results
Content Click below to navigate Investor presentation through the document April 28, 2026 Company overview Financial review Q1 2025 Conclusions Appendix Results References Q1 2026 Investor presentation Results February 4, 2025 Novartis Q1 Results | April 28, 2026 1
Slide 2: Disclaimer
Content Click below to navigate through the document Disclaimer Company overview Financial review This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “plan,”
Slide 3: Company overview
Content Click below to navigate through the document Company overview Financial review Conclusions Company Appendix References overview Company overview Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q1 Results | April 28, 2026 3
Slide 4: Strong start to the year across priority brands and launches
Content Click below to navigate through the document Novartis delivered a strong start to the year across priority brands Company overview and launches, while advancing our pipeline Financial review Conclusions USD bn, % cc1 Q1 pipeline highlights Appendix -5% Rhapsido® EC approval in CSU (April), c
Slide 5: Growth drivers continued strong momentum, up +34% cc in Q1
GROWTH Content Click below to navigate through the document Growth drivers continued their strong momentum, up +34% cc1 in Q1, Company overview supporting our ability to grow through generic erosion on a FY basis Financial review Conclusions Q1 Sales Sales Growth vs. PY Growth vs. PY Appendix USD mi
Slide 6: Kisqali Q1 sales grew +55% cc
GROWTH Content Click below to navigate through the document Kisqali® Q1 sales grew +55% cc, outpacing CDK4/6 market and competition Company overview Financial review Conclusions Sales evolution US eBC NBRx1 Kisqali Competitor 1 Competitor 2 US: +58% in Q1 Appendix USD m, % cc 80% 70% • Continued mBC
Slide 7: Kesimpta Q1 sales grew +26% cc
GROWTH Content Click below to navigate through the document Kesimpta® Q1 sales grew +26% cc, ahead of both MS and B-cell markets Company overview Financial review Conclusions Sales evolution US: +23% in Q1 Appendix USD m, % cc • Demand-led growth with TRx +21% vs. PY, +2%pts market share and +1.5%pt
Slide 8: Pluvicto Q1 sales grew +70% cc
GROWTH Content Click below to navigate through the document Pluvicto® Q1 sales grew +70% cc, driven by US pre-taxane mCRPC Company overview demand and continued ex-US rollout Financial review Conclusions Sales evolution Strong Q1 performance, with continued momentum in US pre-taxane Appendix USD m,
Slide 9: Leqvio Q1 sales grew +69% cc
GROWTH Content Click below to navigate through the document Leqvio® Q1 sales grew +69% cc, with strong growth in China Company overview Financial review Conclusions Sales evolution US: +31% in Q1, outpacing advanced lipid-lowering market1,2 Appendix USD m, % cc • MOTRx +41% vs. PY (market +34%), hig
Slide 10: Scemblix Q1 sales grew +79% cc
GROWTH Content Click below to navigate through the document Scemblix® Q1 sales grew +79% cc, with continued NBRx leadership Company overview in US and early-line launch momentum ex-US Financial review Conclusions Sales evolution US 1L NBRx Share (R3M)1 US: +86% in Q1 Appendix USD m, % cc Competitor
Slide 11: Cosentyx Q1 sales broadly stable
GROWTH Content Click below to navigate through the document Cosentyx® Q1 sales were broadly stable, impacted by one-time effects in US; Company overview continuing to advance new indications Financial review Conclusions Sales evolution US HS Naive NBRx Share (R4W)1 US: -6% in Q1 Appendix USD m, % cc
Slide 12: Renal portfolio rollout continues; Fabhalta and Vanrafia
GROWTH Content Click below to navigate through the document Renal portfolio rollout continues; final Phase III data for Fabhalta Company overview and Vanrafia expected to support traditional FDA approvals in IgAN Financial review Conclusions Fabhalta Vanrafia Appendix Commercial Q1 sales +103% cc, w
Slide 13: Rhapsido CSU launch off to a strong start
GROWTH Content Click below to navigate through the document Rhapsido® CSU launch off to a strong start in US, with first steps ex-US; Company overview positive Phase III results in CIndU reinforce pipeline-in-a-pill potential Financial review Conclusions CSU Encouraging US launch uptake Early US acc
Slide 14: Positive Phase II results for remibrutinib in food allergy
INNOVATION Content Click below to navigate through the document Positive Phase II results for remibrutinib in food allergy support potential Company overview as a fast-acting oral option; Phase III study on track to start in H2 Financial review Conclusions Responders to DBPC-FC at week 41 Compelling
Slide 15: Completed acquisition of Avidity
INNOVATION Content Click below to navigate through the document Completed acquisition of Avidity, adding three late-stage medicines for Company overview neuromuscular disease; Q1 publications underscore transformative potential Financial review Del-zota: 1-year results from EXPLORE44 and Del-desiran
Slide 16: Significant pipeline readouts in the rest of the year
INNOVATION Content Click below to navigate through the document Significant pipeline readouts in the rest of the year Company overview Financial review Conclusions Select readouts CRM Immunology Neuroscience Oncology Appendix References H1 H2 Rhapsido® CIndU Pelacarsen CVRR-Lp(a) Rhapsido HS PhIII P
Slide 17: Financial review and 2026 guidance
Content Click below to navigate through the document Company overview Financial Financial review Conclusions reviewFinancial and review Appendix References 2026 guidance and 2026 guidance Mukul Mehta Chief Financial Officer Mukul Mehta Chief Financial Officer Novartis Q1 Results | April 28, 2026 17
Slide 18: US generic erosion weighed on Q1 results as expected
FINANCIAL PROFILE Content Click below to navigate through the document US generic erosion weighed on results in Q1 as expected; Company overview core margin decline driven by higher R&D investments Financial review Conclusions Key figures1 Q1 Q1 Change vs. PY Appendix USD million, unless indicated o
Slide 19: Continued focus on Free Cash Flow generation
FINANCIAL PROFILE Content Click below to navigate through the document Continued focus on Free Cash Flow generation Company overview Financial review Conclusions Free Cash Flow1 Q1 2026 broadly in USD billion Appendix line despite lower -2% References core operating income 3.4 3.3 Q1 2025 Q1 2026 1.
Slide 20: Shareholder-friendly capital allocation strategy
FINANCIAL PROFILE Content Click below to navigate through the document Continuing our shareholder-friendly capital allocation strategy Company overview Financial review Conclusions Appendix Investing in the business Returning capital to shareholders References Investments in organic business Consist
Slide 21: Reaffirming 2026 full year guidance
FINANCIAL PROFILE Content Click below to navigate through the document Reaffirming 2026 full year guidance Company overview Financial review Conclusions Expected, barring unforeseen events; growth vs. PY in cc1 Appendix Net expected to grow Core operating expected to decline sales income References
Slide 22: 2026 H1 impacted by US generic erosion
FINANCIAL PROFILE Content Click below to navigate through the document 2026 H1 impacted by Entresto®, Tasigna® and Promacta® US Gx1; Company overview on track to deliver H1 and FY guidance Financial review Conclusions 2026 growth vs. PY (cc)2 Appendix Illustrative References Net sales Core2 operatin
Slide 23: Expected currency impact for Q2 and full year 2026
FINANCIAL PROFILE Content Click below to navigate through the document Expected currency impact for Q2 and full year 2026 Company overview Financial review Conclusions Currency impact vs. PY Appendix %pts, assuming late-April exchange rates prevail in 2026 References Actual Simulation 1. Core result
Slide 24: Conclusions
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix References Conclusions Conclusions Vas Narasimhan, M.D. Chief Executive Officer Vas Narasimhan, M.D. Chief Executive Officer Novartis Q1 Results | April 28, 2026 24
Slide 25: Strong start in 2026; on track for FY guidance
Content Click below to navigate through the document Company overview Financial review Delivered a strong start in 2026 Remain on track Conclusions across priority brands and launches to deliver our FY guidance Appendix References Continued to advance our pipeline Multiple readouts in H2 and complet
Slide 26: Appendix
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Appendix Financial performance Innovation: Clinical trials Appendix Abbreviations References Novartis Q1 Results | April 28, 2026 26
Slide 27: Key innovation milestones in 2026
INNOVATION Content Click below to navigate through the document Key innovation milestones in 2026 Company overview 2026 selected key events (expected) H1 2026 H2 2026 Status as of end Q1 Financial review Rhapsido® CIndU US Regulatory Pluvicto® mHSPC US, JP, CN Conclusions decisions Rhapsido® CSU EU
Slide 28: Our pipeline projects at a glance
INNOVATION Content Click below to navigate through the document Our pipeline projects at a glance Company overview Financial review Conclusions Phase I/II Phase III Registration Total Appendix Innovation: Pipeline overview Oncology 15 11 1 27 Financial performance Innovation: Clinical trials Solid t
Slide 29: Novartis pipeline in Phase I
INNOVATION Content Click below to navigate Novartis pipeline in Phase I 13 lead indications through the document Lead indication Oncology Neuroscience Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) EDK060 EDK060 - Charcot-Marie-Tooth disease Financial review Sol
Slide 30: Novartis pipeline in Phase II
INNOVATION Content Click below to navigate Novartis pipeline in Phase II 22 lead indications through the document Lead indication Oncology Immunology Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) GHZ339 GHZ339 - Atopic dermatitis Financial review Solid tumors G
Slide 31: Novartis pipeline in Phase III
INNOVATION Content Click below to navigate Novartis pipeline in Phase III 9 lead indications through the document Lead indication Oncology Neuroscience Company overview Code Name Mechanism Indication(s) Code Name Mechanism Indication(s) BAF312 Mayzent® S1P1,5 receptor modulator Multiple sclerosis, p
Slide 32: Novartis pipeline in registration
INNOVATION Content Click below to navigate Novartis pipeline in registration 1 lead indication through the document Lead indication Oncology Company overview Code Name Mechanism Indication(s) Financial review Solid tumors AAA617 Pluvicto® Radioligand therapy target PSMA Metastatic hormone sensitive
Slide 33: Novartis submission schedule: new molecular entities
INNOVATION Content Click below to navigate through the document Novartis submission schedule New Molecular Entities: Lead and supplementary indications Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2026 2027 2028 ≥2029 Conclusions del-zota del-desiran 225
Slide 34: Submission schedule: existing brands
INNOVATION Content Click below to navigate through the document Novartis submission schedule Supplementary indications for existing brands Company overview CRM Immunology Neuroscience Oncology Non-core TA project Financial review 2026 2027 2028 ≥2029 Conclusions Cosentyx® Fabhalta® Lutathera® Fabhal
Slide 35: Net debt increased by USD 16.2bn
Content Click below to navigate through the document Net debt1 increased by USD 16.2bn, as FCF was more than offset mainly Company overview by M&A and the annual dividend payment Financial review Conclusions USD billion -16.2 Appendix Innovation: Pipeline overview Financial performance Innovation: C
Slide 36: IR Clinical Studies
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview IR Clinical Studies Financial performance Innovation: Clinical trials Clinical Trials Update > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience
Slide 37: Cardiovascular, Renal and Metabolic
Content Click below to navigate through the document Company overview Financial review Cardiovascular, Conclusions Appendix Cardiovascular, Innovation: Pipeline overview RenalRenal andandMetabolic Financial performance Innovation: Clinical trials Metabolic > C ardiovascular, Renal and Metabolic > I
Slide 38: abelacimab - FXI inhibitor
Content abelacimab – FXI inhibitor Click below to navigate through the document Company overview NCT05712200 LILAC (CMAA868A2302) Financial review Indication Atrial fibrillation (AF) Phase Phase 3 Conclusions Patients 1900 Primary Efficacy: Time to first event of ischemic stroke or systemic embolism
Slide 39: atrasentan - ETA receptor antagonist
Content atrasentan - ETA receptor antagonist Click below to navigate through the document Company overview NCT04573478 ALIGN (CHK01-01) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 404 Primary Change in proteinuria Time Frame: Up to Week 24 or approximately 6 months
Slide 40: Fabhalta - CFB inhibitor
Content Fabhalta® - CFB inhibitor Fabhalta® - CFB inhibitor Click below to navigate through the document Company overview NCT04578834 APPLAUSE-IgAN (CLNP023A2301) NCT05755386 APPARENT (CLNP023B12302) Financial review Indication IgA nephropathy Indication Immune complex-mediated membranoproliferative
Slide 41: Leqvio - siRNA (regulation of LDL-C)
Content Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT03705234 ORION-4 (CKJX839B12301) NCT05030428 VICTORION-2P (CKJX839B12302) Financial review Indication Hypercholesterolemia inc. Heterozygous Familial H
Slide 42: Leqvio - siRNA (regulation of LDL-C)
Content Leqvio® - siRNA (regulation of LDL-C) Click below to navigate through the document Company overview NCT05739383 VICTORION-1P (CKJX839D12302) Financial review Indication CVRR (Primary prevention) Phase Phase 3 Conclusions Patients 14111 Primary Time to the first occurrence of 4P-MACE Appendix
Slide 43: LTP001 - SMURF1 Inhibitor
Content LTP001 - SMURF1 Inhibitor Click below to navigate through the document Company overview NCT06649110 (CLTP001A12202) Financial review Indication Pulmonary arterial hypertension Phase Phase 2 Conclusions Patients 232 Primary Part A- Number of participants with Adverse events (AEs) and Serious
Slide 44: PAC001 - anti-IL6 mAb
Content PAC001 – anti-IL6 mAb Click below to navigate through the document Company overview NCT06362759 TRANQUILITY (CPAC001A12201) Financial review Indication ASCVD Phase Phase 2 Conclusions Patients 143 Primary Evaluate the effects of TOUR006 compared with placebo on hs-CRP Appendix Outcome Innova
Slide 45: pelacarsen - ASO targeting Lp(a)
Content pelacarsen - Antisense oligonucleotide (ASO) Click below to navigate targeting Lp(a) through the document Company overview NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Financial review Indication Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein(a) Con
Slide 46: QCZ484
Content QCZ484 Click below to navigate through the document Company overview NCT06857955 (CQCZ484A12201) Financial review Indication Hypertension Phase Phase 2 Conclusions Patients 380 Primary Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by Appendix Outcome ambulatory b
Slide 47: zigakibart - Anti-APRIL
Content zigakibart - Anti-APRIL Click below to navigate through the document Company overview NCT05852938 BEYOND (CFUB523A12301) Financial review Indication IgA nephropathy Phase Phase 3 Conclusions Patients 383 Primary Change from baseline in eGFR Appendix Outcome Innovation: Pipeline overview Meas
Slide 48: DII235
Content DII235 Click below to navigate through the document Company overview NCT07235046 (CDII235A12201) Financial review Indication Risk reduction in cardiovascular disease w elevated Lp(a) Phase Phase 2b Conclusions Patients 200 Primary 1) Time averaged percentage change from baseline in Lp(a) mea
Slide 49: Immunology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Immunology Financial performance Innovation: Clinical trials Immunology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-mar
Slide 50: GHZ339
Content GHZ339 Click below to navigate through the document Company overview NCT06947993 PLATFORM-AD (CADPT17A12201) Financial review Indication Atopic dermatitis Phase Phase 2 Conclusions Patients 224 Primary Outcome Change from baseline in the Eczema Area and Severity Index (EASI) score at Appendi
Slide 51: GIA632 - IL-15 mAb
Content GIA632 – IL-15 mAb Click below to navigate through the document Company overview NCT07431177 (CGIA632B12201) NCT07220577 (CGIA632A12201) Financial review Indication Non-segmental Vitiligo Indication Atopic dermatitis Phase Phase 2 Phase Phase 2 Conclusions Patients 210 Patients 84 Primary Pe
Slide 52: ianalumab - Lupus Nephritis
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05126277 SIRIUS-LN (CVAY736K12301) Financial review Indication Lupus Nephritis Phase Phase 3 Conclusions Patients 420 Primary Outcome Frequency and percentage of parti
Slide 53: ianalumab - Systemic lupus erythematosus
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor depletor through the document Company overview NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) Financial review Indication
Slide 54: ianalumab - Systemic sclerosis
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT06470048 VENUSS (CVAY736S12201) Financial review Indication Systemic sclerosis Phase Phase 2 Conclusions Patients 200 Primary 3/5 Revised Composite Response Index in S
Slide 55: Rhapsido - BTK inhibitor
Content Rhapsido - BTK inhibitor Click below to navigate through the document Company overview NCT05976243 (CLOU064M12301) Financial review Indication Chronic inducible urticaria Phase Phase 3 Conclusions Patients 348 Primary 1. Proportion of participants with complete response in Total Fric Score;
Slide 56: Rhapsido - BTK inhibitor
Content Rhapsido - BTK inhibitor Click below to navigate through the document Company overview NCT06799000 RECHARGE1 (CLOU064J12301) NCT06840392 RECHARGE2 (CLOU064J12302) Financial review Indication Hidradenitis suppurativa Indication Hidradenitis suppurativa Phase Phase 3 Phase Phase 3 Conclusions
Slide 57: Neuroscience
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Neuroscience Financial performance Innovation: Clinical trials Neuroscience > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n
Slide 58: Del-desiran - siRNA DMPK knockdown
Content Del-desiran – siRNA DMPK knockdown Click below to navigate through the document Company overview NCT06411288 HARBOR (CEWF980A12301) Financial review Indication Myotonic Dystrophy Type 1 (MD1) Phase Phase 3 Conclusions Patients 159 Primary Hand function – video Hand Opening Time (vHOT) Append
Slide 59: Del-brax - siRNA DUX4 knockdown
Content Del-brax – siRNA DUX4 knockdown Click below to navigate through the document Company overview NCT07038200 FORTITUDE-3 (CDWH213A12301) Financial review Indication Facioscapulohumeral Muscular Dystrophy (FSHD) Phase Phase 3 Conclusions Patients 200 Primary Quantitative Muscle Testing (QMT) com
Slide 60: Del-zota - PMO mediated exon skipping
Content Del-zota – PMO mediated exon 44 skipping Click below to navigate through the document Company overview NCT06244082 EXPLORE44OLE (CKPE179A12201) Financial review Indication Duchenne Muscular Dystrophy (DMD) Phase Phase 2 Conclusions Patients 39 Primary Incidence of Treatment Emergent Adverse
Slide 61: Fabhalta - CFB inhibitor
Content Fabhalta® - CFB inhibitor Click below to navigate through the document Company overview NCT123456 APPRAISE (CLNP023Q12301) Financial review Indication Generalized Myasthenia Gravis (gMG) Phase Phase 3 Conclusions Patients 146 Primary Change from baseline to Month 6 in Myasthenia Gravis Activ
Slide 62: Kesimpta - anti-CD20
Content Kesimpta® - anti-CD20 Click below to navigate through the document Company overview NCT06869785 FILIOS (COMB157Q12301) Financial review Indication Multiple Sclerosis new dosing regimen Phase Phase 3 Conclusions Patients 180 Primary Ofatumumab plasma pharmacokinetics - area under the curve, u
Slide 63: Mayzent - S1P1,5 receptor modulator
Content Mayzent® - S1P1,5 receptor modulator Click below to navigate through the document Company overview NCT04926818 NEOS (CBAF312D2301) Financial review Indication Multiple Sclerosis, pediatrics Phase Phase 3 Conclusions Patients 120 Primary Annualized relapse rate (ARR) in target pediatric parti
Slide 64: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT05147220 REMODEL-1 (CLOU064C12301) NCT05156281 REMODEL-2 (CLOU064C12302) Financial review Indication Multiple Sclerosis, relapsing Indication Multiple Sclerosis, relapsi
Slide 65: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT06744920 RELIEVE (CLOU064O12301) Financial review Indication Myasthenia Gravis (MG) Phase Phase 3 Conclusions Patients 180 Primary Change from baseline to Month 6 in Myasthenia Gravis Activity of Da
Slide 66: remibrutinib - BTK inhibitor
Content remibrutinib - BTK inhibitor Click below to navigate through the document Company overview NCT07225504 REMASTER (CLOU064P12301) Financial review Indication Secondary progressive multiple sclerosis Phase Phase 3 Conclusions Patients 1275 Primary Time to 6-month confirmed disability progressio
Slide 67: VHB937 - TREM2 stabilizer and activator
Content VHB937 - TREM2 stabilizer and activator Click below to navigate through the document Company overview NCT0664381 ASTRALS (CVHB937B12201) NCT07094516 (CVHB937A12201) Financial review Indication Amyotrophic Lateral Sclerosis (ALS) Indication Alzheimer's Disease (AD) Phase Phase 2 Phase Phase 2
Slide 68: Votoplam - Huntington modulator
Content Votoplam – Huntington modulator Click below to navigate through the document Company overview NCT07326709 INVEST-HD (CHTT227A12301) Financial review Indication Huntington’s Disease (HD) Phase Phase 3 Conclusions Patients 770 Primary Change from Baseline in cUHDRS score Appendix Outcome Innov
Slide 69: Oncology
Content Click below to navigate through the document Company overview Financial review Conclusions Appendix Innovation: Pipeline overview Oncology Financial performance Innovation: Clinical trials Oncology > C ardiovascular, Renal and Metabolic > I mmunology > N euroscience > O ncology > I n-market
Slide 70: 225Ac-PSMA-617 - Radioligand therapy
Content 225Ac-PSMA-617 - Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT06855277 AcTFirst (CAAA817B12301) NCT06780670 PSMAcTION (CAAA817A12201) Financial review Indication Metastatic castration-resistant prostate cancer Indication post Lu Metastatic
Slide 71: ianalumab - 1L Immune Thrombocytopenia
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05653349 VAYHIT1 (CVAY736I12301) Financial review Indication 1L Immune Thrombocytopenia Phase Phase 3 Conclusions Patients 225 Primary Time from randomization to treat
Slide 72: ianalumab - Warm autoimmune hemolytic anemia
Content ianalumab - BAFF-R inhibitor, ADCC-mediated B-cell Click below to navigate depletor through the document Company overview NCT05648968 VAYHIA (CVAY736O12301) Financial review Indication Warm autoimmune hemolytic anemia Phase Phase 3 Conclusions Patients 90 Primary Binary variable indicating w
Slide 73: iptacopan - CFB inhibitor
Content iptacopan - CFB inhibitor Click below to navigate through the document Company overview NCT04889430 APPELHUS (CLNP023F12301) NCT05935215 APPRECIATE (CLNP023F12302) Financial review Indication Atypical haemolytic uraemic syndrome Indication Atypical haemolytic uraemic syndrome Phase Phase 3 P
Slide 74: Lutathera - Radioligand therapy target SSTR
Content Lutathera® - Radioligand therapy target SSTR Click below to navigate through the document Company overview NCT06784752 NETTER-3 (CAAA601A62301) Financial review Indication Gastroenteropancreatic neuroendocrine tumors Phase Phase 3 Conclusions Patients 240 Primary Progression Free Survival (P
Slide 75: Pluvicto - Radioligand therapy target PSMA
Content Pluvicto® - Radioligand therapy target PSMA Click below to navigate through the document Company overview NCT05939414 PSMA-DC (CAAA617D12302) Financial review Indication Oligometastatic prostate cancer Phase Phase 3 Conclusions Patients 450 Primary Metastasis Free Survival (MFS) Appendix Out
Slide 76: luxdegalutamide - Androgen receptor degrader
Content luxdegalutamide - Androgen receptor protein degrader Click below to navigate through the document Company overview NCT07047118 (CJSB462B12201) NCT06991556 (CJSB462C12201) Financial review Indication Metastatic castration resistant prostate cancer Indication Metastatic hormonal sensitive pros
Slide 77: Vijoice - PI3Ki
Content Vijoice® - PI3Ki Click below to navigate through the document Company overview NCT05948943 EPIK-L1 (CBYL719P12201) Financial review Indication Lymphatic Malformation Phase Phase 2/3 Conclusions Patients 230 Primary Outcome Stage 2: Radiological response rate at Week 24 of Stage 2 (adult and
Slide 78: In-market Brands & Global Health
Content Click below to navigate through the document Company overview Financial review In-market Brands Conclusions Appendix In-market Brands Innovation: Pipeline overview & Global Health Financial performance Innovation: Clinical trials & Global Health > C ardiovascular, Renal and Metabolic > I mmu
Slide 79: ganaplacide/lumefantrine - malaria
Content ganaplacide/lumefantrine - Non-artemisinin Click below to navigate plasmodium falciparum inhibitor through the document Company overview NCT05842954 KALUMA (CKLU156A12301) Financial review Indication Malaria, uncomplicated Phase Phase 3 Conclusions Patients 1720 Primary PCR-corrected adequat
Slide 80: Rydapt - Multi-targeted kinase inhibitor
Content Rydapt® - Multi-targeted kinase inhibitor Click below to navigate through the document Company overview NCT03591510 (CPKC412A2218) Financial review Indication Acute myeloid leukemia, pediatrics Phase Phase 2 Conclusions Patients 20 Primary Occurrence of dose limiting toxicities Appendix Outc
Slide 81: EDI048
Content EDI048 Click below to navigate through the document Company overview NCT07249463 (CEDI048A12201) Financial review Indication Cryptosporidiosis infection Phase Phase 2 Conclusions Patients 80 Primary Average stool grade after the initiation of EDI048 or placebo treatment Appendix Outcome Inno
Slide 82: Abbreviations
Content Click below to navigate through the document Abbreviations Company overview Financial review Abbreviation Full form Abbreviation Full form Abbreviation Full form 1L First-line FA Food Allergy n/M Number of participants who completed DBPC-FC 2L Second-line FDA Food and Drug Administration at
Slide 83: References 1 of 3
Content Click below to navigate through the document References 1 of 3 Company overview Financial review Conclusions Kisqali® (slide 6 references) 1 IQVIA Market Sizing Monthly Report, Feb 2026, rolling 3 months; Data lag ~ 2 months. 2 Of CDK4/6 market, US rolling 3 months ending Feb 2026, IQVIA Bre
Slide 84: References 2 of 3
Content Click below to navigate through the document References 2 of 3 Company overview Financial review Conclusions Leqvio® (slide 9 references) 1 Includes PCSK9 monoclonal antibodies and bempedoic acid. 2 MOTRx Q4 QTD ending Mar 20, 2026 vs. PY. Appendix 3 V-INITIATE secondary analyses presented d
Slide 85: References 3 of 3
Content Click below to navigate through the document References 3 of 3 Company overview Financial review Conclusions Rhapsido® (slide 13 references) 1 Internal Novartis analysis leveraging multiple data sources, including IQVIA claims (LAAD, Xponent, DDD), Komodo claims. 2 Estimated using IQVIA Mark